Business Context and Reporting Period
Pediatrix Medical Group, Inc. filed its Quarterly Report on Form 10-Q for the period ended June 30, 2005. The Company operates as a management company for physician group practices, primarily specializing in neonatal and maternal-fetal medicine. As of July 29, 2005, there were 23,726,366 shares of common stock outstanding.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2005 | Six Months Ended June 30, 2004 |
|---|---|---|
| Net Patient Service Revenue | $337.9 million | $300.3 million |
| Net Income | $45.1 million | $46.6 million |
| Diluted EPS | $1.91 | $1.84 |
| Operating Cash Flow | $53.9 million | $33.3 million |
| Cash and Cash Equivalents | $5.6 million | $19.7 million (end of period 2004) |
| Working Capital | $29.2 million | $21.2 million (Dec 31, 2004) |
| Line of Credit Outstanding | $45.2 million | $54.0 million (Dec 31, 2004) |
| Goodwill | $653.8 million | $588.9 million (Dec 31, 2004) |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 12.5% ($37.6 million) year-over-year. Approximately 51.6% of this increase was driven by acquisitions, while same-unit revenue grew 6.2% due to increased patient volume in neonatal and maternal-fetal services.
- Net Income Decline: Despite revenue growth, net income decreased 3.1% ($1.5 million). This decline was primarily due to a $6.0 million increase in estimated liability reserves related to a settlement offer for pending federal and state investigations (Medicaid and TRICARE).
- Operating Margin Compression: Operating margin decreased to 21.7% from 24.8% in the prior year, largely attributable to the $6.0 million reserve adjustment and a shift in payor mix toward lower-reimbursing government programs.
- Acquisition Activity: The Company acquired nine physician group practices for approximately $65.9 million in cash during the six-month period, resulting in $65.0 million in new goodwill.
- Expense Increases: Practice salaries and benefits rose 15.0% to support acquisition growth and volume increases. General and administrative expenses increased 27.9%, driven by the aforementioned legal reserve and growth-related costs.
Outlook, Risks, and Contingencies
- Legal Investigations: The Company is subject to ongoing investigations by the FTC regarding competition issues and by federal/state authorities regarding Medicaid and TRICARE billing practices. A "qui tam" (whistleblower) complaint was filed under seal in July 2005. While a $6.0 million reserve was established, management cannot assure that losses will not exceed this amount.
- Accounting Changes: The Company will adopt FAS 123R (Share-Based Payment) effective January 1, 2006, which will require expensing stock-based compensation. This is expected to have a significant impact on future results of operations.
- Liquidity: The Company maintains a $225 million revolving line of credit, with $45.2 million outstanding as of June 30, 2005. Management believes cash from operations and available credit are sufficient to fund working capital and acquisitions for the next 12 months.
- Subsequent Events: Following the quarter-end, the Company acquired one additional practice for $4.8 million and awarded 339,000 shares of restricted stock to key employees.
Investor Verification Checklist
- Verify the status and potential financial impact of the ongoing federal Medicaid/TRICARE investigations and the adequacy of the $6.0 million reserve.
- Monitor the shift in payor mix toward government-sponsored programs and its effect on future reimbursement rates and margins.
- Assess the impact of the upcoming adoption of FAS 123R on reported net income starting in 2006.
- Review the integration progress and revenue contribution of the nine practices acquired in the first half of 2005.
- Confirm compliance with financial covenants on the $225 million line of credit, particularly regarding net worth and dividend restrictions.